Radiation Therapy for Management of T1–T2 Glottic Cancer at a Private Practice

Abstract

Patients with limited T1aN0 cancers may be treated with either transoral laser excision or RT. Those with more advanced T1-T2N0 cancers are treated with definitive RT. We do not advocate elective nodal irradiation, even for those with bulky T2B malignancies. The addition of concomitant weekly cisplatin 30 mg/M² is considered for patients with T2B cancers. Open parotid laryngectomy is reserved for salvage of suitable patients with a local recurrence.

Differences in survival outcome between stage I and stage II glottic cancer: A SEER‐based analysis

“…Local recurrence rates have been reported to be higher for T2 compared to T1 (75% vs. 93%, both treated with definitive RT), although these rates equalized after accounting for the success of salvage surgery (94% vs. 97%) . Other studies have reported no significant difference in local control and survival . One of these studies did report particularly worse local control outcomes with T2b patients, recommending that additional initial treatment may be optimal in these cases .…”

“…[1][2][3][4] There have been conflicting reports of worse survival outcomes for stage II, but most of these studies have been retrospective case reviews at single institutions with small sample sizes. [5][6][7][8][9] To our knowledge, there have been no large-scale population-based studies evaluating outcomes in early stage glottic cancers due to the relative rarity of this cancer.…”

Dosimetric and radiobiologic comparison of 3D conformal, IMRT, VMAT and proton therapy for the treatment of early‐stage glottic cancer

“…The purpose of treating T1/T2 laryngeal cancer is to cure the disease with larynx function preservation, most specifically the maintenance of voice function and quality . Many past researches have regarded RT as the mainstay of treatment for such patients .…”

Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

“…In recent papers [32,33], concurrent systemic platinum-based chemotherapy was recommended, preferably weekly cisplatin (30 mg/m2), for patients with T2 tumors with impaired cord mobility. As suggested in these studies, the current recommended strategy for T2 GC is CRT, and CRT for early GC will likely become more common worldwide in the near future.…”